The aims of the present study are to define the prevalence of Pulmonary Hypertension (PH) in a cohort of Idiopathic Pulmonary Fibrosis (IPF) patients, to investigate any correlations between systolic pulmonary artery pressure (PAPs) and functional data, to evaluate clinical progress and to compare long-term survival in IPF patients with and without PH. A population of 126 IPF patients was recruited. A high prevalence of PH (39.7%, 50/126), evaluated by echocardiography on the basis of PAPs> 36 mmHg, was mainly observed in smokers and female patients. Regression analysis revealed a significant correlation between PAPs> 50 mmHg and DLCONA (p=0.0294). Mean PAPs was significantly greater one year after onset of PH (p=O.Ol). 11/21 patients with FVC <50% had a significant increase in PAPs one year after onset of PH (p=0.02). There was a highly significant difference between survival of IPF patients with and without PH (p=O.OOOl; hazard ratio = 3.56). This study revealed that PH has a high prevalence in patients with IPF and is associated with increased risk of mortality. Early diagnosis of IPF patients with pulmonary hypertension is important, so that they can be enrolled in waiting lists for lung transplant as soon as possible.
There is growing interest in the study ofpulmonary hypertension (PH) associated with interstitial lung diseases (ILD), especially idiopathic pulmonary fibrosis (IPF) (1, 2) , due to the consequences of PH for the prognosis and therapy of this serious disease. Several retrospective studies indicate that PH is frequently associated with IPF, though its incidence and prevalence remain unclear. Estimates vary widely, depending on patient population, disease severity and diagnostic methods (3) (4) (5) (6) (7) (8) (9) (10) . According to the latest classification, PH exists when mean pulmonary artery pressure (PAPm), evaluated by right heart catheterization (RHC), exceeds 25 mmHg at rest (1) . Pathological aspects of PH in IPF include vascular remodelling of arteries, arterioles and venules, destruction of the capillary bed, thrombosis in situ and vascular regression in areas of dense fibrosis (6) . Parenchymal fibrosis and subsequent vascular obstruction and destruction are considered the main determinants of the pathogenesis of PH in IPF patients, but the low correlation between severity of PH and functional data suggests that other mechanisms are also involved (3, 11) . In particular, FVC is not correlated with PH (5, 6, 11, 12) , suggesting that factors other than progressive fibrosis are responsible for PH in IPF. Pathogenesis is not well defined, but fibrosis, chronic hypoxemia, vasoconstriction, in situ thrombosis, vascular remodelling and inflammation, altered gene expression and endothelial dysfunction may be major mechanisms involved (13) (14) (15) (16) (17) .
The history and clinical status ofIPF generally do not suggest PH, because appropriate tests are needed to diagnose it and patients complain of dyspnoea in any case. Doppler echocardiography (DE) is a useful non-invasive technique for screening IPF patients for PH, but the gold standard is RHC (18, 19) . Early or disproportionate alteration of diffusing capacity of the lung for carbon monoxide (DLCO) with respect to lung volume may suggest PH (3, 5, 6, 12, 20) .
PH is a disorder of prognostic importance affecting many IPF patients. In recent years, it has been demonstrated that PH increases the risk of death (5, 6, 18, 20) There has been controversial data about effective therapy for these patients, due to an absence of multicenter clinical trials specifically addressed to the treatment of PH in IPF patients, and only data on small cohorts in the literature (21) . A recent single clinical trial was designed to evaluate the efficacy of ambrisentan on IPF, but was stopped for lack of evidence. Lung transplant is the only treatment that improves survival in IPF (21) .
As the prevalence and pathogenesis of PH in IPF are still unclear and no effective therapy is available (l), we designed the present study to define the prevalence ofPH in a numerous cohort ofIPF patients, to investigate any correlations between systolic pulmonary artery pressure (PAPs) and functional data, to evaluate clinical progress and to compare long-term survival in IPF patients with and without PH.
MATERIALS AND METHODS

Population
Weevaluated 126patients diagnosed with IPF since 200 1 at Siena Regional Referral Centre for ILD. General features of these patients are shown in Table I . All patients satisfied ATSIERSdiagnostic criteria for IPF, and 33 underwent lung biopsy. Patients with radiological evidence of combined fibrosis and pulmonary emphysema were excluded (22, 23) . Auto-immune serology and rheumatology evaluation were carried out for all patients to exclude systemic vasculitis and other connective tissue diseases. Patients with venous thromboembolism, portal hypertension, left ventricular dysfunction, heart valve disorders and any cause ofIP other than IPF were not included.
All patients were tested for PH at diagnosis ofIPF, and underwent lung function tests (LFT), DLCO measurement, arterial blood gas analysis (ABG), six minute walking test (6MWT), high resolution computer tomography of the chest (HRCT) and DE during follow-up. Only 37 patients underwent RHC. We did not correlate LFT, 6MWT and ABG parameters of patients with and without PH as test timing could not be matched. PAPs was calculated by quantifying tricuspid regurgitant jet velocity and inferior vena cava diameter/collapsibility index. Doppler signal from tricuspid regurgitation was adequate in all patients. RHC was performed (on 37 patients) to confirm PH or to obtain access to the lung transplant waiting list. RHC was performed through the femoral vein and the following heart hemodynamic parameters were measured: systolic pulmonary artery pressure (PAPs), mean pulmonary artery pressure (PAPm), pulmonary capillary wedge pressure (PWP), pulmonary vascular resistance (PVR) and cardiac output. PH was defined as PAPs> 36 mmHg, evaluated by DE, or PAPm > 25 mmHg and PWP < 15 mmHg evaluated by RHC.
LFT and DLCO were measured using a plethysmograph according to ATSIERS standards (24, 25) and corrected for temperature and barometric pressure. Valueswere expressed as a percentage of predicted reference values. FEVl, FVC, VC IN, TLC, RY, DLCO and DLCONA were recorded. Arterial blood samples for ABG were drawn from the brachial or radial artery to evaluate Sp02, pa02, paC02 and pH (in room air or with oxygen). 6MWT was performed according to the American Thoracic Society protocol (26) . Chest HRCT was evaluated by expert radiologists.
Patients and controls gave a written informed consent to enrolment in the study that was approved by the local ethics committee.
Statistical analysis
Statistical analysis was performed by MedCalc Statistical Software (Version 9), Graph Pad Prism 5 and SAS v.8.0. The prevalence of PH in female and smoker patients was calculated by Yates corrected X 2 • Correlation analysis was based on Pearson's productmoment correlation if the data had a normal distribution according to the Shapiro-Wilk test, otherwise it was based on Spearman's rank correlation. The correlation between PAPs (DE) and PAPs (RHC) was examined using Spearman's rank correlation and a Bland-Altman plot was generated to further examine the precision of the data (27) . The Wilcoxon rank test was used to analyse PAPs after 12 months of observation. The survival curve was calculated by Kaplan Meyer analysis.
Data were expressed as mean and standard deviation.
RESULTS
A high prevalence of PH (39.7%, 50/126) Table I . A significant difference was found between female and male groups (X 2 Yates correction=4.93, p=0.02) and in the prevalence of smoking between patients with and without PH (X 2 Yates correction= 12.11, p=0.0005, Table I ).
Mean PAPs, functional features and gas exchange paramenters of patients with PH evaluated by DE are shown in Table II . As this table shows, PH was independent of patient functional status and when patients were divided on the basis ofFVC percentages (greater or less than 50%), no significant difference in PAPs was found between the two groups. Fig. 1and Table III show the characteristics ofIPF patients in whom PH was confirmed by RHC. There was a significant but weak correlation between PAPs evaluated by DE and RHC in 37 patients (p=0.0167 r=0.408). Bland-Altman analysis indicated a mean difference between the two methods of 0.08108 mmHg, while the standard deviation was 13.93. The limits of agreement (-28.04 +27.88) were large enough to be sure that DE-RVSP should not be used to replace RHC measurement of PAPs (Fig. 2) .
Considering parameters at PH diagnosis (in the PH subgroup), no associations between PAPs (by DE) and FEV1, FVC, TLC, p02 levels, walking test distance, nadir or desaturation percentage were found. A significant inverse correlation between PAPs and DLCONA ratio was observed in the subgroup of patients with PAPs>50 mmHg by DE (p=0.0294, r=-0.62611, Fig. 3 ). This correlation was not confirmed in the whole population, where only a trend was observed. Hemodynamic parameters (PAPm, PAPs, RPV, PWP) for the group of patients with PAPm > 25 mmHg by RHC (23 patients) did not reveal any association with lung function test Fig. 5 ). By contrast, in 11/21 patients with PH and FVC < 50% (excluding 10: 3 transplanted, 5 deceased, 2 lost to follow-up), we observed a significant increase in PAPs (p=0.0293) ( Fig. 6 ). Thus PH may be independent of functional status, but PAPs only increased significantly in patients with severe restrictive deficit.
Median survival of patients with PH was 36 months. There was a highly significant difference in survival between IPF patients with and without PH (p=O.OOOI; hazard ratio = 3.56; Fig. 7) . Median survival for all 126 patients was 60 months. Median survival of patients without PH could not be calculated because fewer than 50% died in the observation period. When patients were divided on the basis of FVC (greater or less than 50%), no difference in survival time was observed. 
data on the epidemiology ofthis severe complication, ranging from 32% to 84% (3-10, 28) depending on the different IPF populations and methods used for diagnosis ofPH. Interestingly, PH was more prevalent in IPF smokers than non-smokers in our study, in line with King et al. (29) . Several reports describe a higher frequency of pulmonary arterial hypertension (group 1 in the Dana Point classification) in females than males (2:1) of the general population (30) , and also in our IPF population PH was more prevalent in women than men. Connective tissue diseases as well as vasculitis were consistently excluded from our study. The prevalence of PH in women is an interesting result but is not easy to interpret. Our study revealed a 39.7% prevalence of PH in IPF patients. The literature shows a wide range of 6MWT distance and Sp02 nadir were not correlated with PAPs values (7) . Similarly we found that pa02 values, 6MWT distance and desaturation percentages were not correlated with PAPs. Spirometric and plethysmographic data was not correlated with echocardiographic parameters in our patients, in line with reports in the literature (3-6, 8, 20, 28) .
All these results support the evidence that PH is independent of the severity of parenchymal fibrotic disease and that there are different phenotypes ofIPF that require further study. DLCONA proved to be the only parameter correlated with PAPs evaluated by Doppler echocardiogram in our study and in other populations (3, 5, 6, 12, 20) .
Doppler echocardiography could be useful for screening PH in IPF patients, but its accuracy is low. RHC remains the gold standard for diagnosis of PH. The unfortunate disadvantage of RHC is its invasiveness. The lack of any effective therapy for IPF patients with PH throws doubt on the real need for such an accurate but expensive and invasive examination. In our study, RHC revealed a modest increase in PAPm (28.4±3.3 mmHg), probably detected at an early stage. Alternatively, patients may have died before any sharp increase in PH, or the PH-IPF phenotype does not develop very high PH.
Our data suggests that patients with FVC<50% at diagnosis of PH have a worse prognosis than those with FVC>50%. In fact patients with lower FVC showed an increase in PAPs after an observation period of 12 months, though the survival rate did not differ in the two groups. PH occurred regardless of functional status, but was probably associated with a worse prognosis in patients with poorer lung function.
Although the prognosis ofIPF is in any case severe, the onset of PH can further influence prognosis. As expected, the survival of our PH-IPF patients was significantly worse than that of IPF patients without PH, in line with previous observations (5, 6, 20) . It is therefore urgent to identify the phenotype, pathogenic mechanisms, genetic susceptibility and environmental factors affecting the natural history of PH-IPF in order to identify therapeutic targets and drugs that could change the prognosis. The latest guidelines do not contain any specific indications about therapy for IPF-PH.
In conclusion, our study confirms that PH has a high prevalence in patients with IPF, especially females and smokers. PH is independent of the severity of functional status. PH is not severe in IPF patients compared with idiopathic pulmonary arterial hypertension. It can be difficult to achieve high diagnostic accuracy in IPF patients because of their poor general condition, which excludes invasive procedures such as right heart catheterization. New non-invasive diagnostic parameters with high sensitivity and specificity are needed. PH patients with FVC<50% showed a significant increase in PAPs 12 months after diagnosis. Early diagnosis of PH is crucial: PH is associated with high mortality in IPF patients, who should therefore be enrolled in waiting lists for lung transplant as soon as possible.
